These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 2107997

  • 21. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL, Sandlund JT, Miser JS, Arasi V, Linehan M, Magrath IT.
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [Abstract] [Full Text] [Related]

  • 22. Nursing implications in the administration of ifosfamide and mesna.
    Richters JE.
    Oncol Nurs Forum; 1990 May; 17(2):276. PubMed ID: 2107534
    [No Abstract] [Full Text] [Related]

  • 23. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
    Scheulen ME, Niederle N, Bremer K, Schütte J, Seeber S.
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():93-101. PubMed ID: 6414700
    [Abstract] [Full Text] [Related]

  • 24. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
    Araujo CE, Tessler J.
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):195-201. PubMed ID: 6402369
    [Abstract] [Full Text] [Related]

  • 25. Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():1-192. PubMed ID: 6414687
    [No Abstract] [Full Text] [Related]

  • 26. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
    Benjamin RS, Legha SS, Patel SR, Nicaise C.
    Cancer Chemother Pharmacol; 1993 Sep; 31 Suppl 2():S174-9. PubMed ID: 8453693
    [Abstract] [Full Text] [Related]

  • 27. Clinical overview of mesna.
    Burkert H.
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():175-81. PubMed ID: 6414692
    [Abstract] [Full Text] [Related]

  • 28. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, Souhami RL.
    Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
    [Abstract] [Full Text] [Related]

  • 29. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP, Houle JM, Bush DA, Li JT, Newman CE, Brade WP.
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [Abstract] [Full Text] [Related]

  • 30. Ifosfamide vs cyclophosphamide in cancer therapy.
    Weiss RB.
    Oncology (Williston Park); 1991 May; 5(5):67-76; discussion 76-82, 84-6. PubMed ID: 1653004
    [Abstract] [Full Text] [Related]

  • 31. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
    Pendyala L, Creaven PJ, Schwartz G, Meropol NJ, Bolanowska-Higdon W, Zdanowicz J, Murphy M, Perez R.
    Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
    [Abstract] [Full Text] [Related]

  • 32. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M, Fujiwara F, Todo S, Morioka Y, Imashuku S.
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [Abstract] [Full Text] [Related]

  • 33. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
    Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC.
    Gynecol Oncol; 1996 Oct; 63(1):25-7. PubMed ID: 8898163
    [Abstract] [Full Text] [Related]

  • 34. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP, Epelman S, Bush DA.
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
    [Abstract] [Full Text] [Related]

  • 35. Mesna excretion and ifosfamide nephrotoxicity in children.
    Goren MP, Pratt CB, Meyer WH, Wright RK, Dodge RK, Viar MJ.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7153-7. PubMed ID: 2510931
    [Abstract] [Full Text] [Related]

  • 36. High-dose ifosfamide and mesna therapy in the outpatient setting.
    Heinzman K.
    J Intraven Nurs; 1992 Dec 15; 15(6):322-6. PubMed ID: 1484311
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.
    Ormstad K, Orrenius S, Låstbom T, Uehara N, Pohl J, Stekar J, Brock N.
    Cancer Res; 1983 Jan 15; 43(1):333-8. PubMed ID: 6401168
    [Abstract] [Full Text] [Related]

  • 38. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
    Otero JC, Solidoro A, Casanova L, Vallejos C, Rodriguez W.
    J Exp Ther Oncol; 1996 Mar 15; 1(2):84-7. PubMed ID: 9414391
    [Abstract] [Full Text] [Related]

  • 39. Recent experience with ifosfamide/mesna in solid tumors. International satellite symposium to the 3rd European Conference on Clinical Oncology. Stockholm, June 1985. Proceedings.
    Cancer Chemother Pharmacol; 1986 Mar 15; 18 Suppl 2():S1-58. PubMed ID: 3102087
    [No Abstract] [Full Text] [Related]

  • 40. Phase II trial of ifosfamide in children with malignant solid tumors.
    Pratt CB, Horowitz ME, Meyer WH, Etcubanas E, Thompson EI, Douglass EC, Wilimas JA, Hayes FA, Green AA.
    Cancer Treat Rep; 1987 Feb 15; 71(2):131-5. PubMed ID: 3100034
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.